Bariatric Surgery and Cancer Risk: What 33 Years of Follow-Up in the Swedish Obese Subjects Study Reveal

When I counsel patients considering bariatric surgery, most of the conversation naturally centers on diabetes remission, blood pressure, joint pain, and quality of life. Cancer risk reduction comes up less often, partly because the data supporting it, while real, has taken decades to mature into something we can discuss with real confidence. Two analyses published this year from the landmark Swedish Obese Subjects (SOS) study — one in PLOS Medicine in January, another in Scientific Reports in May — now give us some of the longest and most detailed follow-up data available on this question, and they clarify both how real this benefit is and, importantly, who benefits most.

The SOS study is one of the most valuable long-term datasets in obesity medicine precisely because of its duration. Researchers at the University of Gothenburg have followed more than 4,000 individuals with obesity since the early 1990s, roughly half of whom underwent bariatric surgery and half of whom received usual non-surgical obesity care, now tracking outcomes for up to 33 years. Few studies in any area of medicine follow patients this long, which is what makes findings from this cohort so valuable for questions — like cancer risk — that unfold over decades rather than months.

The 2026 analyses focused specifically on sex-based differences and genetic factors influencing cancer outcomes after surgery. The clearest signal in the data was that weight loss following bariatric surgery was linked to both lower cancer incidence and lower cancer-related mortality in women, but this protective association was not observed in men in the same way. Within the female participants, genetic background further modified the effect: women who carried a particular variant of the FTO gene — a gene well known in obesity research for its association with body weight and fat mass — experienced roughly 47 percent lower breast cancer risk after surgery-related weight loss. Among women who carried both the FTO variant and had elevated insulin levels at baseline, the risk reduction reached approximately 64 percent. The cancers most affected were breast and gynecological cancers, both of which have well-established biological links to excess adiposity through mechanisms including elevated estrogen production in fat tissue and chronic hyperinsulinemia, which can promote tumor cell growth.

Why the sex difference? The leading biological explanation relates to how obesity drives cancer risk through hormonally sensitive pathways that are simply more active and more consequential in women — particularly estrogen production in adipose tissue, which is a major driver of breast and endometrial cancer risk in postmenopausal women specifically. Obesity is also associated with elevated cancer risk in men, notably for cancers like esophageal, colorectal, kidney, liver, and pancreatic cancer, but the SOS data suggest the surgical weight-loss benefit on cancer risk in men either operates through different pathways not fully captured in this analysis, or requires different genetic or metabolic subgroups to become detectable — an area that needs further dedicated research.

I think it is important to be precise about what this does and does not mean for patients. This is not evidence that bariatric surgery prevents cancer in a simple, universal way, and it should never be the primary reason someone chooses to have surgery — that decision should rest on the full picture of a patient's metabolic health, mobility, cardiovascular risk, and quality of life. What this data does responsibly support is a more complete conversation, particularly with women who have a family history of breast or gynecological cancer, elevated insulin levels, or known obesity-related genetic risk factors, about the fact that sustained, substantial weight loss appears to meaningfully lower their long-term cancer risk, not simply their metabolic risk.

This finding also reinforces a broader pattern I discuss often: obesity is not simply a risk factor for diabetes and heart disease. The World Health Organization's International Agency for Research on Cancer now recognizes obesity as a contributing cause of at least 13 distinct cancer types. Data like this, tracking real patients for over three decades, is what allows us to move from that general statistical association to something more specific and more clinically actionable — namely, which patients are most likely to see a meaningful reduction in cancer risk from durable weight loss, and roughly how large that benefit might be.

For my patients, particularly women with a personal or family history of breast or gynecological cancer who are also considering bariatric surgery for metabolic reasons, this is worth raising directly in your consultation, alongside a broader discussion of your individual risk factors and whether genetic counseling might add useful information to your decision-making.

Sources: Swedish Obese Subjects (SOS) study analyses, University of Gothenburg — PLOS Medicine (January 2026) and Scientific Reports (May 2026).